## **Key Findings**

- •Several gut-derived, and disease-associated metabolites can be measured in breath either at steady state, and after administration of certain substrates.
- Given ease of use of breath collection, this approach can be used on large cohorts to better establish the effect of these metabolites on diseases.

## **1. Background and Objectives**

- •Gut dysbiosis results in excessive production of metabolites that may exacerbate certain diseases, for example gut ethanol production has been associated with NASH.
- •Many of these metabolites can be measured non-invasively on breath.
- •We investigated the feasibility of quantification of these metabolites in breath with and without substrate intervention.

## 2. Methods

- •For each intervention healthy subjects were enrolled after overnight fasting. Breath was analyzed before and after substrate administration.
- •Breath analysis was performed using selected ion flow tube mass spectrometry (SIFT-MS) with direct sampling, or with GC-MS.




Figure 1. Substrate intervention process.


### **3. Results**


- •Fermentation products associated with non-alcoholic fatty liver disease (NAFLD) and gut discomfort show a spike on breath after substrate administration.
- •Metabolites generated by amino acid metabolism also show a spike after substrate ingestion.
- •Additional metabolites associated with neurodegenerative diseases can be detected.


### 4. Conclusions

- Many metabolites generated by gut bacteria and associated with different diseases are detectable in breath.
- •This non-invasive method can replace the current need for blood collection allowing scaling to large cohort populations.










**Table 1.** Subject characteristics for glucose

oer	10
le) n	7/3
an rs)	29[28-37]
dian 3)	62[54-70]
an m²)	23[22-25]

# Gut Microbiome Phenotyping Using Dynamic Breath Analysis

Ahmed T. Murgia A. Banda I. Ahmed Y. Manhota M. Ricciardi F. Sweeney K. Nicholson-Scott L. McConville L. Gandelman O. Allsworth M. Boyle B. Ferrandino G.

Owlstone Medical, United Kingdom



nol	Propanol	Acetaldehyde	Dimethyl sulfide	Propanoic acid	Methyl mercaptan	Propanol
ine	Trimethilamine	Indole	Acetic acid	2,3 butanediol	Pentane	1,2 Propandiol